



PROFFES

TREND PORTFOLIO 2.0

US-Options and Stocks



Wednesday, December 25, 2024

Contents

Editorial

- [Setting Up for 2025](#)

Stock Portfolio

- [Eli Lilly \(NYSE: LLY\)](#)

Option Portfolio

[Well prepared for a big January](#)

Dear Reader,

First and foremost, I wish you a happy Christmas and/or Hanukah. It's certainly a bit odd to have this holiday and New Year's Day in the middle of the week.

I'm guessing the market makers aren't thrilled they have to work around holidays to get the requisite trading done by the end of the year...

and it has been a wild one.

Once again, after stabilizing and moving up, the stock market had another temper tantrum because the Federal Reserve had the nerve to say that the economy continues to purr along and there may be less rate cuts in 2025. Inflation is still a little hot, and the biggest economic engine on the planet is running at a bit higher RPM than usual.

That great news caused a massive selloff, even though the Fed cut rates by the expected quarter point.

Usually, December is a time when the big financial companies clear out investment losses for taxes and also sell winners to add to cash.

A new administration in Washington and the talks of tariffs may inspire some people to sit in bonds or cash for the first quarter to see how things shake out.

We're still doing well, and as we begin our third year, I'm very excited for our portfolios.

My new options-only service, [Proffe's Options Trader \(POT\)](#), launched in early September. We've already made 14 roundtrip trades and we're averaging 39.1% per trade! There's no long-term commitment and it's just \$99 per month! [Click here to learn more.](#)

Best Regards,

Michael Proffe



LLY: Adding Sleep Apnea to the Demand

Timing couldn't be more perfect for an update on **Eli Lilly (NYSE: LLY)**.

Just this week, LLY announced that its weight loss drug, Zepbound, has been approved by the US Food and Drug Administration for use with sleep apnea.

Now that LLY has finally caught up with demand for Zepbound after opening a new manufacturing facility, this sleep apnea news is like a turbo charger on top of its already robust growth.


As you can see below, LLY wasn't first to the game when this new generation of type 2 diabetes drugs and subsequent weight loss versions started.

As you can see in this chart, it's catching up quickly.

Closing the Gap

Sales of Lilly's drugs surged in the second quarter

■ Ozempic ■ Wegovy ■ Mounjaro ■ Zepbound



Source: Novo Nordisk, Eli Lilly

Bloomberg

Source: Bloomberg

This is how the big drug companies latch on to their biggest blockbusters. You get a drug approved for a particular treatment, then apply for various other co-morbidities. The massive volume of evidence provided for initial FDA approval allows for a much faster approval lane and magnifies the potential revenue stream and earnings growth.

Lipitor, Humira, and Keytruda are the three leading moneymakers, but there's a very good chance we'll be seeing LLY and its competitors vying for a spot among these names and likely surpassing them with an obesity drug.

There are nearly a billion people worldwide that suffer from sleep apnea, and 10% of America suffers from sleep apnea. That's a huge market, especially as a side door for access to Zepbound for overweight people that don't have a diagnosis like obesity or diabetes.



Source: American Medical Association

This leverages an already blockbuster drug to new heights, and Ozempic hasn't been approved for sleep apnea, so now these 30 million (and likely more) potential customers are all LLY's.

LLY is far more than a one-hit wonder.

It has one of the largest pipelines and libraries of existing drugs in the industry. LLY's diversification is a direct result of its longevity, but it has also curated its portfolios over time with some of the smartest scientists in the labs, as well as shrewd leaders in the corporate suites.

Also, it's the ideal pick for long-term growth investors because it has a uniquely long view of its growth. It isn't going to risk a bad product to be first when it can use the knowledge of the company that goes first to market in a new sector to better plan its entry.

Then once establish, LLY will open up new avenues for that successful drug for use with other conditions. There are no surprises with this kind of thinking, but that's what makes them so challenging to pull off well.

LLY's ability to pull this off so well with Mounjaro and Zepbound should confirm to any skeptic that LLY is just getting started.

Total Portfolio Overview

Our **combined portfolio performance has delivered 428%** in the past two years.


That's an average of 120.37 % per year. That's better than any major average out there, and the outlook remains bullish for at least the first half of next year.

Our quality MegaTrend picks are doing well, which is why we hold long-term growth stocks and options. They rebuild the losses quickly since they both represent the best stocks in the markets, and the options move even faster to regain ground.

The true value in this service is holding both the stocks and the long-term options because they work in synergy with one another, and that holds true even when we experience selloffs.

PORTFOLIO INFORMATION COMBINED			
START DATE:	11-16-2022	START AMOUNT:	\$30,000.00
CURRENT DATE:	12-25-2024	CASH:	\$789.44
TOTAL TODAY:	\$158,692.78	PERFORMANCE:	428.98% \$128,692.78

Performance of Combined Stock & Options Portfolio Since Launch





Stock Portfolio

The portfolio is up 113 % since this time in 2022. Don't forget, we're pulling down those numbers with just 10 stocks. It goes to show that long-term growth investing is not as boring as some investors think!

Buying the best companies in MegaTrend sectors means our stocks hold up well in selloffs and bounce back faster when the bulls start running again. Case in point: We're still sitting on very solid returns, averaging more than 43 % a year.

PORTFOLIO INFORMATION STOCK				
START DATE:	11-16-2022	START AMOUNT:	\$10,000.00	
CURRENT DATE:	12-25-2024	CASH:	\$608.44	
TOTAL TODAY:	\$21,391.78	PERFORMANCE:	113.92%	\$11,391.78

Performance of Stock Portfolio Since Launch





Symbol	Name	P-Date	P, total	P/Size	Price	Value, total	Earnings	E. [%]	Size
NVDA	NVIDIA	11-23-2022	988.92	16.48	141.35	8,481.00	7,492.08	757.60	60
META	META PLATFORMS	05-30-2023	797.25	265.75	605.34	1,816.02	1,018.77	127.79	3
LLY	ELI LILLY	11-16-2022	1,058.79	352.93	794.50	2,383.50	1,324.71	125.12	3
AAPL	APPLE	11-16-2022	1,041.53	148.79	257.58	1,803.06	761.53	73.12	7
AMZN	AMAZON	01-16-2024	1,073.59	153.37	228.54	1,599.78	526.19	49.01	7
ISRG	INTUITIVE SURGICAL	05-30-2024	807.20	403.60	533.01	1,066.02	258.82	32.06	2
IBM	IBM	12-02-2024	904.32	226.08	222.93	891.72	-12.60	-1.39	4
FI	FISERV	12-02-2024	878.52	219.63	207.59	830.36	-48.16	-5.48	4
ORCL	ORACLE	12-02-2024	912.20	182.44	171.08	855.40	-56.80	-6.23	5
ARM	ARM HOLDINGS	07-01-2024	1,248.08	156.01	132.06	1,056.48	-191.60	-15.35	8
TOTAL			9,710.40			20,783.34	11,072.94	114.03	

ABBREVIATION	EXPLANATION
Symbol	Exchange symbol
ISIN	The Internationally Securities Identification Number (ISIN) is a 12-character letter figure
P-date	Purchase date
P, total	The complete purchase price of the respective position
P/size	Share price
Price	Current price
Value, total	Current total value of the position
Earnings	Profit and losses
E. [%]	Profit and losses in %

Closed Stock Positions

To provide a clearer picture of the total return, we have added a table to show our closed stock positions in the portfolio.

Name	P-Date	P, Total	P/Size	S-Date	S, Total	S/Size	Earnings	E [%]	# of Shares
ALPHABET	05-30-2023	867.16	123.88	12-02-2024	1,212.05	173.15	344.89	39.77	7
APPLIED MATER	05-30-2024	658.05	219.35	12-02-2024	537.21	179.07	-120.84	-18.36	3
ASML	11-30-2022	1,161.64	580.82	12-02-2024	1,374.42	687.21	212.78	18.32	2
MASTERCARD	11-23-2022	1,048.11	349.37	07-01-2024	1,405.96	468.65	357.85	34.14	3



Options Portfolio

This portfolio is up 586.51 % in just two years!


The market has given the us the opportunity to make some big moves in this portfolio in recent weeks, and we've taken full advantage!

We're well positioned for the remainder of 2024 and the beginning of '25 at this point. We have a great collection of long dated positions, so we can settle into the new year without much concern for our current opportunities.

Remember: If you like my options, but want a bit more action, you'll love my new options-only service, [Proffe's Options Trader](#) (POT). We've already made **14 round trip trades for a \$14,420 profit**, with an **average holding time of 19 days**. And at just **\$99 per month**, it pays for itself fast! [Click here to learn more.](#)

PORTFOLIO INFORMATION OPTION			
START DATE:	11-30-2022	START AMOUNT:	\$20,000.00
CURRENT DATE:	12-25-2024	CASH:	\$181.00
TOTAL TODAY:	\$137,301.00	PERFORMANCE:	586.51% \$117,301.00

Performance of Options Portfolio Since Launch





Open Options Positions

As a friendly reminder, contracts in **RED** are sells and contracts in **GREEN** are buys.

Option-Name	Name	P-Date	Expirationdate	P, total	P/Size	Price	Value, total	Earnings	E. [%]	Contracts
AMZN250620C190	AMAZON	06-26-2024	06-20-2025	11,500.00	28.75	48.71	19,484.00	7,984.00	69.43	4
AAPL260116C240	APPLE	12-03-2024	01-16-2026	6,030.00	30.15	41.31	8,262.00	2,232.00	37.01	2
AMZN260116C210	AMAZON	11-13-2024	01-16-2026	13,820.00	34.55	45.75	18,300.00	4,480.00	32.42	4
SAP251219C250	SAP	12-03-2024	12-19-2025	5,540.00	27.70	32.90	6,580.00	1,040.00	18.77	2
ANET260116C107.5	ARISTA NET	11-07-2024	01-16-2026	8,645.00	21.61	25.56	10,224.00	1,579.00	18.26	4
TSM260116C200	TAIWAN SEM	10-21-2024	01-16-2026	19,625.00	39.25	39.50	19,750.00	125.00	0.64	5
NVDA250919C140	NVIDIA	11-25-2024	09-19-2025	10,360.00	25.90	25.85	10,340.00	- 20.00	-0.19	4
META260116C650	META	12-05-2024	01-16-2026	17,610.00	88.05	82.25	16,450.00	- 1,160.00	-6.59	2
ORCL251219C185	ORACLE	11-07-2024	12-19-2025	7,635.00	25.45	18.75	5,625.00	- 2,010.00	-26.33	3
INTU260116C710	INTUIT	11-13-2024	01-16-2026	10,740.00	107.40	66.50	6,650.00	- 4,090.00	-38.08	1
FI250919C220	FISERV	11-25-2024	09-19-2025	9,460.00	23.65	13.30	5,320.00	- 4,140.00	-43.76	4
CTAS251219C220	CINTAS COR	11-07-2024	12-19-2025	7,905.00	26.35	10.00	3,000.00	- 4,905.00	-62.05	3
DELL250620C135	DELL TECHN	06-05-2024..(2)	06-20-2025	15,130.00	30.26	8.75	4,375.00	- 10,755.00	-71.08	5
NVO260116C120	NOVO NORDI	12-03-2024	01-16-2026	11,070.00	18.45	4.60	2,760.00	- 8,310.00	-75.07	6
TOTAL				155,070.00			137,120.00	- 17,950.00	-11.58	

Closed Options Positions

To provide a clearer picture of the total return, we have added a table to show our closed options positions in the portfolio.

Optionname	P-Date	P, Total	P/Size	S-Date	S, Total	S/Size	Earnings	E [%]	Contracts
META250620C460	02-05-2024	8,540.00	85.40	12-04-2024	17,010.00	170.10	8,470.00	99.18	1
AMD250620C175	01-24-2024	9,030.00	45.15	12-02-2024	1,710.00	8.55	-7,320.00	-81.06	2
GOOG250620C175	05.06.2024..(2)	14,015.00	28.03	12-02-2024	7,575.00	15.15	-6,440.00	-45.95	5
MSFT250620C410	02-05-2024	10,940.00	54.70	12-02-2024	8,990.00	44.95	-1,950.00	-17.82	2
NKE250620C95	06-05-2024	3,660.00	12.20	12-02-2024	711.00	2.37	-2,949.00	-80.57	3
PFE250620C30	05-23-2024	10,200.00	2.55	12-02-2024	2,440.00	0.61	-7,760.00	-76.08	40
NVDA250620C150	06-26-2024	18,550.00	18.55	11-18-2024	20,000.00	20.00	1,450.00	7.82	10
AMZN250620C155	01-16-2024	10,760.00	26.90	11-12-2024	23,460.00	58.65	12,700.00	118.03	4
AAPL250620C185	06-27-2023	3,465.00	34.65	10-30-2024	5,440.00	54.40	1,975.00	57	1
AAPL251219C220	13.06.2024..(2)	14,485.00	28.97	10-30-2024	17,950.00	35.90	3,465.00	23.92	5
CAT250620C340	22.02.2024..(2)	12,075.00	40.25	10-15-2024	20,988.00	69.96	8,913.00	73.81	3
MU250620C125	05-23-2024	9,660.00	24.15	06-20-2024	16,640.00	41.60	6,980.00	72.26	4
NVDA250620C104	05-23-2024	23,110.00	23.11	06-20-2024	41,950.00	41.95	18,840.00	81.52	10
GOOG250620C145	02-05-2024	9,380.00	23.45	05-29-2024	18,320.00	45.80	8,940.00	95.31	4



PROFFES

TREND PORTFOLIO

US-Options and Stocks

2.0

<p>Chief Editor: Editor: Michael Proffe US Editor: Gregg Early Proffe Invest Inc. P.O Box 549 Wilton NH 03086, USA</p>	<p>Copyright © 2024 by Proffe Invest Inc. All rights reserved. Printed in USA. Protected by copyright laws of the United States and international treaties. This report may only be used pursuant to the subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the World Wide Web), in whole</p>	<p>or in part, is strictly prohibited without the express written permission of Proffe Invest Inc. For the protection of our subscribers, if copyright laws are violated, the subscription will be terminated.</p> <p>Information, opinion, research and commentary contained herein are obtained from sources believed to be reliable; their correctness, completeness or reliability, however, cannot be guaranteed.</p> <p><u>Recommendations, opinions or suggestions are given with the understanding that subscribers acting on information assume all risks involved! Investments recommended in</u></p>	<p><u>this report should be made only after reviewing the prospectus or financial statements of the company.</u> Proffe's Trend Portfolio does not provide individual investment advice, or act as an investment adviser, or individually advocate the purchase or sale of any security or investment. Neither Proffe Invest Inc. nor our employees are compensated in any way by the companies whose stocks or options we recommend.</p>
---	--	---	---